Azenta, Inc. (NasdaqGS:AZTA) will seek M&A. Chief Financial Officer Lindon Robertson said, "we make our investments continuously for organic growth and then incremental M&A. And we clearly, every time we make an acquisition, we expect that we're going to continue to see growth and invest behind that to build out the company. we aim to take that and all cash generated now toward investments for the future in terms of both feeding our business and for strategic M&A".
Azenta, Inc. is a provider of biological and chemical compound sample exploration and management solutions for the life sciences industry. The Companyâs segments include Sample Management Solutions, Multiomics and B Medical Systems. The Sample Management Solutions segment offers end-to-end sample management products and services, including sample and repository services and core products (automated stores, cryogenic systems, automated sample tube, and consumables and instruments). The Multiomics segment provides genomic and other sample analysis services, including gene sequencing and gene synthesis. B Medical Systems segment is focused on the manufacturing and distribution of temperature-controlled storage and transportation solutions in international markets to governments, health institutions, and non-government organizations. It provides products and services through its brands, including GENEWIZ, FluidX, Ziath, 4titude, Limfinity, Freezer Pro, Barkey, and B Medical Systems.
AZENTA, INC. 
